Discovering Cancer Bio Markers – This Med Device Company May Soar

Traders Alert – News And Movers Today

Pressure BioSciences – PBIO (OTCQB)

RECENTLY –  Independent research carried out by Chinese and Australian scientists shows that the Pressure BioSciences Pressure Cycling Technology (PCT) platform is excellent for the processing of preserved (formalin-fixed paraffin-embedded, or FFPE) and fresh frozen biopsy tissues, which are considered invaluable for discovering cancer Bio Markers.

Buffetts $128 B Cash – Nothing To Buy

 has formed a base and most recently and rebounded on the news of Zachs placing an initial $4.44 price target on the shares.  With a superb management team in place this Medical Device company we feel is ready to advance to much higher levels.  This company has all the right stuff . Biotech Shares On The Rise – Sector Playing Catch-Up

We urge all serious investors to place these shares on their BUY LIST – Zachs Target of $4.44CEO

Video Interview  Website Products Publications SEC Filings

Fat Brands – FAT NASDAQ – 8.25% Offering Details

Pressure BioSciences Inc.’s (PBIO) Proprietary PCT Platform Demonstrates Ability to Discover Cancer Biomarkers in Independent Research

Pressure BioSciences’ (OTCQB: PBIO) pressure cycling technology (“PCT”) platform was recently the subject of independent research carried out by Chinese and Australian scientists in which the platform demonstrated its proficiency in processing of preserved (“FFPE”) and fresh frozen biopsy tissue samples for the discovery of cancer Bio Markers .

Apple – Life Beyond I-Phone – Target $300 

An article discussing the company reads, “According to Pressure BioSciences president and CEO Richard T. Schumacher, over one billion archival tissue samples exist in pathology and other laboratories across the world. Millions of additional samples are processed and stored every single year. These samples contain an abundance of information that could be key to the discovery of new cancer biomarkers, development of new cancer diagnostics, and release of new treatments and prevention measures, Schumacher concluded. . . . ‘We believe that our PCT platform is establishing itself as the method of choice for the superior extraction of potential biomarkers and their presentation for the effective proteomic analyses that will propel the growth of this huge market,’ Pressure BioSciences’ director of marketing and sales Roxana McCloskey added.” MORE

Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.